Introduction {#s1}
============

The Diabetes Control and Complications Trial (DCCT) enrolled 1,441 patients with type 1 diabetes between 1983 and 1989 ([@B1]). At study entry, participants were randomly assigned to intensive insulin therapy (INT), targeting near-normal glycemia, or conventional insulin therapy (CON) according to the standard of care at that time. Microvascular diabetes complications were assessed during the DCCT, including the development and progression of the peripheral and cardiovascular autonomic manifestations of diabetic neuropathy. In 1993, after an average of 6.5 years of follow-up, the DCCT investigators reported that INT significantly reduced the incidence of diabetic neuropathy, similar to findings for diabetic retinopathy and nephropathy ([@B1]--[@B3]). INT was subsequently widely accepted as the standard of care for type 1 diabetes. At DCCT end, DCCT CON participants were taught INT, and all participants were encouraged to adhere as closely as possible to an intensive diabetes treatment regimen and were returned to their prior health care providers for ongoing care. The observational Epidemiology of Diabetes Interventions and Complications (EDIC) follow-up was established to monitor the long-term effects of prior INT compared with prior CON treatment on the development and progression of more advanced microvascular complications and cardiovascular disease in the DCCT cohort.

Diabetic neuropathy represents a clinically diverse group of disorders having differing anatomic distribution, clinical course, and underlying pathophysiology, but ultimately thought to reflect metabolic and microvascular factors that result in axonal degeneration of large- and small-nerve fibers. The specific presentation of diabetic neuropathy reflects the distribution and size of nerve fibers involved, most commonly presenting as a distal symmetric sensory or sensorimotor neuropathy (diabetic peripheral neuropathy \[DPN\]). Manifestations of autonomic neuropathies, including cardiovascular autonomic neuropathy (CAN), may also develop. Although the specific clinical manifestations are heterogeneous, diabetic neuropathy is a major cause of disability, associated with reduced quality of life and high mortality. In this article, we detail and discuss the diabetic neuropathy outcomes, including DPN and CAN, during DCCT/EDIC.

Research Design and Methods {#s2}
===========================

Detailed descriptions of DCCT and EDIC procedures and baseline characteristics have been described previously ([@B1],[@B4]). The DCCT and EDIC protocols were approved by the institutional review boards of all participating centers, and all participants provided written informed consent. Participation in peripheral and cardiovascular autonomic neuropathy outcome assessments through EDIC years 13/14 are shown ([Fig. 1](#F1){ref-type="fig"}).

![Flow diagram of DCCT/EDIC subject participation in CAN and DPN assessments at EDIC year 13/14. \*Percentage based on the original number of EDIC participants (*n* = 1,375). †Percentage based on number of active EDIC participants at year 13/14 (*n* = 1,274). ‡Percentages shown for R-R variation and Valsalva ratio are based on number of EDIC participants with CAN test at EDIC year 13/14 (*n* = 1,226). DCCT/EDIC CAN testing included R-R variation during deep breathing, Valsalva maneuver, and postural testing. DPN testing included history and examination by a board-certified neurologist and nerve conduction studies. Adapted with permission from Pop-Busui et al. ([@B16]).](31fig1){#F1}

DPN {#s3}
---

DPN was assessed by board-certified neurologists using a standardized evaluation to identify symptoms, signs, and nerve conduction abnormalities consistent with distal symmetrical peripheral neuropathy. These assessments were done at DCCT baseline, after 5 years of DCCT participation and/or at the end of the DCCT, and again during EDIC year 13/14. Vibration perception threshold testing was performed at EDIC year 13/14 using a forced-choice algorithm of decreasing vibration intensity at the dominant index finger and great toe ([@B5]). An annual neuropathy assessment was performed in EDIC using the Michigan Neuropathy Screening Instrument (MNSI), a 15-item symptom questionnaire and a structured examination for foot ulcers, deformities, infections, excessive dryness, and calluses, plus ankle reflexes and distal vibration perception ([@B6]--[@B8]).

### DPN Definitions {#s4}

DPN was defined using a three-level hierarchy of clinical findings and nerve conduction results:1.Clinically evident DPN, defined as at least two positive findings among sensory symptoms, signs, or reflex abnormalities consistent with a distal symmetrical polyneuropathy.2.Abnormal nerve conduction studies, defined by the presence of at least one abnormal nerve attribute (of amplitude, latency, F-wave, or nerve conduction velocity) in two or more nerves among the median, peroneal, and sural nerves.3.Confirmed DPN, defined as the presence of both clinically evident DPN and abnormal nerve conduction studies as defined above. Confirmed DPN was the primary outcome measure of peripheral neuropathy used during DCCT and EDIC.Abnormal vibration perception threshold was defined as a threshold value more than 2.5 SDs above the age-adjusted mean value obtained from nondiabetic referents ([@B5]). The MNSI criterion for DPN was based on a symptom score of ≥7 or a physical examination score of \>2 ([@B6],[@B8]).

CAN {#s5}
---

CAN was assessed at baseline and every 2 years in DCCT using a battery of tests that included R-R variation during deep breathing, the Valsalva maneuver, and postural testing. These tests were repeated in EDIC year 13/14 and again during year 16--17 ([@B9]). Subjects were uniformly prepared for CAN testing by instruction that included fasting; abstaining from caffeine, tobacco, and medications the morning of testing; avoidance of vigorous physical activity and alcohol consumption for 48 h prior to testing; and absence of hypoglycemia prior to and during testing ([@B3],[@B9]).

### CAN Definitions {#s6}

The primary CAN outcome was defined as any of following criteria: R-R variation \<15, R-R variation of \<20 plus a Valsalva ratio ≤1.5, or a decrease of \>10 mmHg in diastolic blood pressure at any point during 10 min of standing after a period of 30 min of supine rest (postural hypotension) ([@B3],[@B9]). In EDIC, secondary CAN outcomes included the age-adjusted R-R variation and Valsalva ratio ([@B9]).

Other Neuropathy-Related Outcomes During EDIC {#s7}
---------------------------------------------

A structured medical history was obtained annually in EDIC including questions regarding the presence of painful or noxious symptoms of peripheral neuropathy, use of medications to treat painful neuropathic symptoms, symptoms of postural hypotension, gastroparesis, diarrhea, colonic atony, genitourinary dysfunction, and hypoglycemic unawareness.

The Uro-EDIC ancillary study was conducted at EDIC year 10 as a cross-sectional evaluation to describe the prevalence of diabetic genitourinary complications, including erectile dysfunction, lower urinary tract symptoms, and urinary incontinence, and to investigate relationships between these and other diabetes complications. Erectile dysfunction was defined as an erectile function domain score of \<20 using the International Index of Erectile Function and by response to a single questionnaire item regarding "confidence to get and keep an erection" ([@B10],[@B11]). Lower urinary tract symptoms were assessed using the American Urological Association Symptom Index with moderate to severe lower urinary tract symptoms defined by scores \>7 ([@B10]). Urinary incontinence in women was measured using a standardized questionnaire ([@B12],[@B13]).

Cardiac magnetic resonance imaging (MRI) was performed during EDIC year 15/16, affording an opportunity to relate cardiac structural and functional information to concurrent CAN findings ([@B14]).

Results {#s8}
=======

DPN {#s9}
---

During DCCT, the prevalence of confirmed DPN increased slightly among INT group participants (from 7 to 9%), but substantially in CON subjects (from 5 to 17%, *P* \< 0.001) ([Table 1](#T1){ref-type="table"}) ([@B2],[@B15],[@B16]). Significant treatment group differences were observed for all measures of incident DPN at the end of the DCCT. Adjusting for the presence of confirmed DPN at baseline, the INT risk reduction for incident neuropathy during the DCCT was 64% (95% CI 45--76) ([@B1]).

###### 

Prevalence of DPN and CAN outcomes at DCCT baseline, DCCT closeout, and EDIC year 13/14 ([@B16])

![](31tbl1)

The prevalence of all measures of DPN increased during EDIC, and treatment group differences continued to be significant ([Table 1](#T1){ref-type="table"}). In EDIC, a 30% reduction in the risk of incident confirmed DPN was observed with prior INT (odds ratio \[OR\] 0.70 \[95% CI 0.52-- 0.93\]) ([Table 2](#T2){ref-type="table"}). Similar magnitude reductions were documented for several nerve conduction study measures ([@B15]).

###### 

Incidence of clinically evident DPN, abnormal nerve conduction studies, and confirmed DPN at DCCT closeout and EDIC year 13/14\* ([@B15])

![](31tbl2)

One explanation for the finding of a persistent benefit of INT for confirmed DPN at EDIC year 13/14 could be the presence of different levels of subclinical neuropathy in the INT and CON groups at DCCT closeout, as any significant group difference in the nerve conduction results could influence the subsequent development of confirmed DPN during EDIC ([@B17]). This possibility was addressed using analytic models of incident neuropathy that adjusted for nerve conduction study results at DCCT closeout. These additional models negated the treatment group differences in development of neuropathy observed during EDIC. Specifically, after correction for difference in nerve conduction study results at DCCT closeout, no significant risk reduction was associated with former INT at EDIC years 13/14 (OR 1.17 \[95% CI 0.84 --1.63\]) ([@B15]).

Logistic regression models were used to evaluate the effect of glycemic control on prevalent and incident DPN in EDIC. The odds of clinically evident DPN, abnormal nerve conduction studies, and confirmed DPN in EDIC (prevalence) each increased per unit (%) increase in DCCT mean HbA~1c~ and EDIC mean HbA~1c~. The incidence of any of the three DPN outcomes during EDIC was increased with each unit increase in mean EDIC HbA~1c~. The DCCT mean HbA~1c~ was associated only with increased odds for incident confirmed DPN in EDIC ([Table 3](#T3){ref-type="table"}) ([@B15]).

###### 

Effect of glycemic exposure in DCCT and EDIC (per unit increase in HbA~1c~) on the odds of prevalent (at EDIC year 13/14) or incident (during EDIC) clinically evident DPN, abnormal nerve conduction study, and confirmed DPN ([@B15])

![](31tbl3)

Vibration perception threshold was abnormally high at the great toe in 57% of former INT subjects versus 64% of former CON subjects (*P* \< 0.05). The vibration perception threshold was lower (indicating better sensitivity) among former INT subjects (3.53 vibration units vs. 4.03 vibration units, *P* \< 0.01) ([@B5]).

The prevalence of DPN as measured by MNSI at the first year of EDIC was 1.8% versus 4.7% in INT and CON, respectively (*P* \< 0.0001) by MNSI questionnaire and 17.8% versus 28.0% (*P* \< 0.0001) by MNSI examination. Significant treatment group effects using MNSI criteria for DPN persisted through at least EDIC year 8. A 1% lower cumulative mean HbA~1c~ (e.g., 8% \[64 mmol/mol\] to 7% \[53 mmol/mol\]) reduced the odds of DPN by 38% and by 27% for the questionnaire and examination, respectively ([@B8]). At year 14 of EDIC, the overall prevalence of DPN using the MNSI examination was 33%, closely mirroring the overall prevalence of concurrently measured confirmed DPN (30%) ([@B7]).

Use of medication for neuropathic pain was reported by 7% of former INT participants and 6% of former CON participants at EDIC year 13/14. The difference was not statistically significant ([@B15]).

CAN {#s10}
---

The prevalence of CAN was very low at the start of the DCCT (4% INT vs. 5% CON, *P* = NS). By DCCT end, the prevalence remained stable in INT, and had almost doubled in CON participants (5% vs. 9%, *P* = 0.0017) ([Table 1](#T1){ref-type="table"}) ([@B3]). The incidence of CAN was reduced by 45% with intensive treatment during the course of the DCCT.

The prevalence of CAN at EDIC year 13/14 was 29% INT vs. 35% CON, *P* = 0.018) ([@B9]). Group differences were primarily driven by differences in R-R variation. The continuous R-R variation remained significantly higher in the INT group compared with the CON group, even after adjusting for important covariates including age, sex, and duration in DCCT (adjusted means 29.9 vs. 25.6, *P* \< 0.001) ([@B9]).

During EDIC, there was a 31% reduction in the risk for incident CAN in INT subjects who were free of CAN at DCCT closeout, with significant risk reductions remaining after adjustments that included age, R-R variation at DCCT closeout, medication use, and several other covariates ([Table 4](#T4){ref-type="table"}) ([@B9],[@B16]). Virtually all of the treatment group difference in the incidence of CAN could be explained by the treatment group differences in mean HbA~1c~ levels over time.

###### 

Incidence of abnormal CAN measurements at EDIC year 13/14 among subjects with intact function at DCCT closeout ([@B9])

![](31tbl4)

Comprehensive cardiovascular disease evaluations carried out during EDIC allowed for additional analyses to understand further the clinical implications of CAN. Associations between CAN and cardiac structure and function were analyzed in 966 EDIC participants with concomitant cardiac MRI and CAN measurements at EDIC year 16 ([@B14]). Although parameters of left ventricle systolic function, including the ejection fraction, did not differ among EDIC participants with and without CAN, those participants with CAN had higher left ventricular mass and mass-to-volume ratios compared with participants without CAN (*P* \< 0.0001 for each), changes consistent with left ventricular concentric remodeling that were independent of age, sex, and other traditional cardiovascular risk factors.

Other Autonomic and Genitourinary Outcomes {#s11}
------------------------------------------

A small number of participants from both former treatment groups reported autonomic symptoms. Decreased adrenergic awareness of hypoglycemia (20% INT vs. 25% CON, *P* = NS) excessive postprandial epigastric fullness (8% INT vs. 8% CON, *P* = NS), and male impotence were among the most commonly reported symptoms at EDIC year 13/14 ([@B9]).

Erectile dysfunction was ascertained in 591 men during EDIC year 10, as part of the Uro-EDIC ([@B18]). Erectile dysfunction was present in 23% of these men. No DCCT treatment group differences were observed for reported erectile dysfunction among men with diabetes duration of 1--5 years and who had no evidence of microvascular complications at DCCT entry (DCCT primary prevention cohort 17% INT vs. 20.3% CON, *P* = 0.49). Significant treatment group difference were observed among men with up to 15 years diabetes duration and retinopathy at DCCT entry (DCCT secondary intervention cohort 12.8% INT vs. 30.8% CON, *P* = 0.001). Age, DPN, and mean DCCT-EDIC HbA~1c~ were significant risk factors associated with the presence of erectile dysfunction ([@B18]). Moderate to severe lower urinary tract symptoms were reported by 20% of men participating in Uro-EDIC and were associated with age and presence of peripheral neuropathy, but not with DCCT treatment group assignment ([@B10]). Of 550 women participating in Uro-EDIC, urinary incontinence was reported by 65%; 17% reported weekly or more frequent incontinence. There was no observed relationship with incontinence and DCCT treatment group assignment or presence of peripheral neuropathy ([@B12],[@B13]).

Conclusions {#s12}
===========

The clinical burdens of diabetic neuropathic complications are well recognized and result in significant morbidity. Painful symptoms are frequently refractory to treatment, and loss of protective sensation heightens the risk for foot ulceration and lower-extremity amputations ([@B19],[@B20]). While symptoms associated with painful DPN and advanced autonomic dysfunction are often particularly troublesome, the earliest manifestations of CAN are silent and easily overlooked in clinical practice. Yet, CAN is an independent predictor of mortality ([@B21],[@B22]), possibly by promoting life-threatening arrhythmias and sudden death in response to a variety of insults including drug side effects, hypoglycemia, hypokalemia, hypotension, or ischemia ([@B23]).

DPN and CAN were uncommon at the start of the DCCT, partly due to the intentional exclusion of people with neuropathy sufficiently severe to require treatment, but were increasingly prevalent over the DCCT/EDIC follow-up. INT during the DCCT decreased the development and progression of confirmed DPN and CAN relative to CON. Remarkably, treatment group differences were still measurable through 14 years of EDIC follow-up despite similar levels of glycemic control during EDIC ([@B9],[@B15]).

The durable impact of prior treatment, even after disappearance of prior glycemic separation, first observed for retinopathy and nephropathy, has been described as "metabolic memory" ([@B24],[@B25]). Confirmed DPN increased in both INT and CON participants by EDIC year 13/14, but the treatment group differences observed for confirmed DPN at that time were eliminated by adjusting for nerve conduction variables at the end of the DCCT. Viewed differently, among subjects who did not have neuropathy at DCCT completion, those in the CON group were shown to have greater degrees of subclinical neuropathy than subjects in the INT group ([@B17]). This subclinical neuropathy represented an asymptomatic neuropathy that had not yet produced clinical signs or sufficiently abnormal electrophysiology and could partially explain the findings of continued difference in the development of DPN in the INT and CON groups during EDIC. Whether an additional influence of early intensive glucose control might have been apparent earlier during EDIC is unknown, but a persistent metabolic effect was not required to explain the durable beneficial effects on confirmed DPN in EDIC ([@B17]).

In contrast, a long-term beneficial influence of early intensive glucose control, first observed for retinopathy and nephropathy, was observed for CAN in EDIC. Modeling that adjusted for R-R variation at DCCT closeout did not negate the INT-associated risk reduction for development of CAN ([@B9]). The risk reduction for CAN is consistent with the "metabolic memory" effect observed for retinopathy and nephropathy ([@B16]). This apparent discordance in the impact of prior DCCT treatment group effect on longer-term outcomes for DPN and CAN may reflect differences in susceptibility of small- and large-nerve fibers to glycemic exposure.

In general, findings from studies of diabetic neuropathies have to be interpreted with caution, given the broad range of diagnostic methods employed and lack of consistency in the criteria used to define neuropathy. In the Wisconsin Epidemiologic Study of Diabetic Retinopathy (WESDR) ([@B26]), DPN was assessed by tactile or temperature sensitivity; and they reported abnormalities in 19--25% and 11--19% of participants, respectively, after 10 years of follow-up. In the Pittsburgh Epidemiology of Diabetes Complications Study (EDC) ([@B27]), the cumulative incidence of DPN over a period of 5.3 years was 29%. In the EURODIAB Prospective Complications Study ([@B28]), an observational study that included 1,172 subjects with type 1 diabetes from 31 centers across Europe, neuropathy was defined by the presence of neuropathic symptoms, absence of ankle or knee reflexes, and abnormal vibration perception threshold as assessed by biothesiometers. EURODIAB reported that after only 7.3 years of follow-up, neuropathy developed in 24% of subjects, considerably higher than the 9% overall incidence of confirmed DPN reported over 5 years of follow-up in DCCT, which arguably used more stringent criteria that included nerve conduction studies. Although the differences in study design do not allow for precise comparisons between the true incidence of neuropathy in the DCCT/EDIC and the EURODIAB cohorts, EURODIAB also reported that HbA~1c~ was an important determinant of neuropathy incidence ([@B28]).

The DCCT/EDIC is the first large study to concurrently obtain high-quality, standardized cardiac MRI and CAN evaluations, allowing for additional analyses regarding clinical implications of CAN ([@B14]). Although these cross-sectional findings prevent analysis of any causal relationship between CAN and ventricular dysfunction, other studies have demonstrated a relationship between sympathetic activation and left ventricular hypertrophy ([@B29],[@B30]).

Genitourinary problems associated with diabetes, with the likely exception of impotence, are frequently overlooked in clinical practice and are rarely considered in the context of diabetic neuropathies. The Uro-EDIC study affords an opportunity to define the extent of genitourinary complications of diabetes and to explore the relationships of these to well-defined micro- and macrovascular complications, including neuropathy. In cross-sectional analyses, both erectile dysfunction and lower urinary tract symptoms in men were associated with DPN, perhaps due to shared or overlapping mechanisms of neuronal damage ([@B10],[@B18]). These cross-sectional findings of associations between male genitourinary complications and DPN must be interpreted cautiously. Uro-EDIC data are being collected longitudinally and this may, in the future, shed light on shared pathophysiologic mechanisms between genitourinary and neuropathic complications.

The EDIC study continues to evaluate risk factors for neuropathic complications in a large number of well-characterized patients with type 1 diabetes and continues to demonstrate the value of optimizing glucose control as early as possible in the course of the disease to ameliorate the long-term effects of hyperglycemia. The DCCT and EDIC confirm that glycemic control is a significant and robust predictor of neuropathy. However, they also show that for most patients with type 1 diabetes, current strategies for optimizing glucose control are insufficient to fully prevent or delay the development of neuropathic complications, as 25% of subjects in the former INT group and 35% of subjects in the former CON group had confirmed DPN by 14 years of EDIC follow-up.

The reproducible, standardized DPN and CAN testing protocols, the robust and consistent definitions of neuropathy outcomes, the large sample size, and, most important, the commitment of DCCT/EDIC participants have allowed the DCCT/EDIC to provide invaluable lessons on the clinical course and the means of ameliorating DPN and CAN in patients with type 1 diabetes ([@B9],[@B15],[@B16]).
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